Who are Bupivacaine, epinephrine, dexamethasone, and clonidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupivacaine-epinephrine-dexamethasone-and-clonidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bupivacaine, epinephrine, dexamethasone, and clonidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bupivacaine, epinephrine, dexamethasone, and clonidine (Bupivacaine, epinephrine, dexamethasone, and clonidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination with adjuvants. Area: Anesthesia/Pain Management.

phase 2 Local anesthetic combination with adjuvants Voltage-gated sodium channels (bupivacaine); alpha-2 adrenergic receptors (clonidine); glucocorticoid receptor (dexamethasone) Anesthesia/Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine, epinephrine, dexamethasone, and clonidine (Bupivacaine, epinephrine, dexamethasone, and clonidine) — Tufts Medical Center. This combination provides local anesthesia via bupivacaine while epinephrine prolongs duration, dexamethasone reduces inflammation, and clonidine enhances analgesia through alpha-2 adrenergic receptor activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine, epinephrine, dexamethasone, and clonidine TARGET	Bupivacaine, epinephrine, dexamethasone, and clonidine	Tufts Medical Center	phase 2	Local anesthetic combination with adjuvants	Voltage-gated sodium channels (bupivacaine); alpha-2 adrenergic receptors (clonidine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination with adjuvants class)

Tufts Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine, epinephrine, dexamethasone, and clonidine — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-epinephrine-dexamethasone-and-clonidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab